MZMatthew S. Zabriskie
Matthew S. Zabriskie
*This is an algorithmically generated author record based on publicly available information.
Research Subjects
Matthew S. Zabriskie has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Anthony D. Pomicter
Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA
21 shared publications Hannah M. Redwine
21 shared publications- Michael W. Deininger
Division of Hematology/Oncology, University of Michigan, Ann Arbor, USA
21 shared publications Phillip M. Clair
21 shared publications- Alexandria van Scoyk
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
20 shared publications - Ami B. Patel
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
20 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia